论文部分内容阅读
目的探讨复方倍他米松注射液对顽固性低频型感音神经性聋的治疗作用。方法对23例单侧低频型感音神经性聋的患者耳后注射复方倍他米松注射液1次,剂量1ml,观察疗效,随访至少6个月以上;同时对4例双侧低频型感音神经性聋的患者进行了相同的治疗。对照组18例单侧低频型感音神经性聋的患者用口服西比灵+敏使朗治疗2周,随访2个月。结果 23例单耳患者中12耳痊愈,7耳听力改善(有效率82.6%),4耳无效。有2例(2耳)患者2～3个月后重新出现低频听力下降的症状。其余患者随访6个月,没有复发。除1例患者耳后局部注射处发现轻度的皮肤萎缩,未发现其他不良反应。4例双侧发病的患者,2例有效,2例无效。2例有效的患者1～2个月后症状复发。对照组18例患者中3例(3耳)停药1周后痊愈,1例(1耳)停药2周后痊愈,随访2个月,没有复发。其余14例无效。结论耳后注射复方倍他米松注射液可以有效地治疗顽固性低频型感音神经性聋,但是对双侧患者疗效差,可能双侧患者多与自身免疫性内耳病有关。
Objective To investigate the therapeutic effect of compound betamethasone on intractable low frequency sensorineural hearing loss. Methods Twenty-three patients with unilateral low-frequency sensorineural deafness were injected with compound betamethasone once a day at a dose of 1 ml. The curative effect was observed for at least 6 months. At the same time, Patients with deafness undergo the same treatment. Control group of 18 patients with unilateral low-frequency sensorineural hearing loss patients with oral sibirin + Minioron treatment for 2 weeks, followed up for 2 months. Results Among the 23 patients with mononeuropathy, 12 ears recovered, 7 ears improved hearing (effective rate 82.6%), 4 ears ineffective. In 2 (2 ears) patients 2 to 3 months later, symptoms of low frequency hearing loss reappeared. The remaining patients were followed up for 6 months without recurrence. Except for 1 patient, mild skin atrophy was found at the local injection site and no other adverse reactions were found. In 4 patients with bilateral disease, 2 were effective and 2 were ineffective. Two patients with effective 1 to 2 months after the recurrence of symptoms. Three of the 18 patients in the control group (3 ears) were cured after stopping for 1 week, and 1 patient (1 ear) recovered after 2 weeks of withdrawal and were followed up for 2 months without recurrence. The remaining 14 cases are invalid. Conclusions The injection of compound betamethasone into the ear can effectively treat refractory low-frequency sensorineural hearing loss, but its effect is poor on bilateral patients. It is possible that bilateral patients are mostly associated with autoimmune inner ear disease.